Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 4/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | MPI | P34949 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039216 | 0.84 | MAOB (0.43) | CASP1KIF11S1PR1S1PR3TOP1 | |
| SCHEMBL1038525 | 0.83 | CASP1 (0.48) | CASP1KIF11TOP1MAOBMKNK1 | |
| SCHEMBL1040447 | 0.83 | MAP4K4 (0.45) | CASP1KIF11S1PR1S1PR3TOP1 | |
| SCHEMBL1349546 | 0.81 | KDM4E (0.46) | MAOBDYRK1ADYRK2KDM4EALDH1A1 | |
| SCHEMBL30041884 | 0.80 | CASP1 (0.56) | CASP1KIF11TOP1MAOBALDH1A1 | |
| SCHEMBL1040032 | 0.79 | SRC (0.45) | CASP1KIF11TOP1MAOBMKNK1 | |
| SCHEMBL5918466 | 0.79 | CASP1 (0.45) | CASP1KIF11TOP1MAOBENPP1 | |
| SCHEMBL30042717 | 0.79 | KIF11 (0.50) | KIF11TOP1MAOBMKNK1MKNK2 | |
| SCHEMBL1041929 | 0.79 | KIF11 (0.50) | KIF11TOP1MAOBMKNK1MKNK2 | |
| SCHEMBL1043167 | 0.79 | KDM4E (0.44) | CASP1KIF11MAOBDYRK1ADYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3168224-A1 | ORGANOZINC COMPOSITION | Ludwig-Maximilians-Universität München (DE) | 2017-05-17 | — | — | EP | disclosed |
| EP-3168224-A1 | ORGANOZINC COMPOSITION | Ludwig-Maximilians-Universität München (DE) | 2017-05-17 | — | — | EP | disclosed |
| EP-1542692-B1 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1542692-B1 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2270006-A1 | Pyridazine derivatives useful as vanilloid receptor ligands | Amgen, Inc (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2270006-A1 | Pyridazine derivatives useful as vanilloid receptor ligands | Amgen, Inc (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7396831-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-01 | — | — | US | disclosed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1542692-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | Amgen Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050070545-A1 | For treatment or prevention of metabolic and cell proliferative diseases; modifying lipid metabolism | TULARIK INC. (US) | 2005-03-31 | — | — | US | disclosed |
| WO-2005013907-A2 | PYRROLO[1,2-B]PYRIDAZINE DERIVATIVES | JAPAN TOBACCO INC. (JP) | 2005-02-17 | — | — | WO | disclosed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003099284-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070545-A1 | For treatment or prevention of metabolic and cell proliferative diseases; modifying lipid metabolism | PC, ACACB, ACAT1 | CASP1 4042/4885KIF11 3316/4885S1PR1 1434/4885 |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CASP1 1477/4885KIF11 2278/4885S1PR1 1267/4885 |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CASP1 1374/4885KIF11 2440/4885S1PR1 1171/4885 |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CASP1 1602/4885KIF11 2210/4885S1PR1 1296/4885 |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CASP1 1433/4885KIF11 2444/4885S1PR1 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.